Although NSCLC patients harboring EGFR mutations generally achieve clinical benefits from EGFR-TKI treatment, most patients show the development of resistance to EGFR-TKIs after approximately 1 year2–5. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.